Table 1 Clinical and biochemical characteristics of CPP and controls
From: The analysis of endocrine disruptors in patients with central precocious puberty
Variable | CPP group (N = 47) | Pre-pubertal Control group (N = 26) | Pubertal Control group (N = 21) | P value |
|---|---|---|---|---|
CA (years) | 8.53 ± 0.65 | 7.03 ± 1.37 | 11.18 ± 1.00 | < 0.001 |
BA (years) | 10.43 ± 0.68 | 6.51 ± 1.93 | 11.39 ± 1.12 | < 0.001 |
Height (cm) | 131.87 ± 5.84 | 113.41 ± 8.47 | 141.05 ± 9.34 | 0.002 |
Height SDS | 0.23 ± 0.97 | − 1.04 ± 0.66 | −0.73 ± 0.86 | < 0.001 |
BMI (kg/m2) | 17.35 ± 2.67 | 15.02 ± 1.72 | 17.36 ± 2.49 | 0.06 |
Tanner stage | 2.5 ± 0.50 (between stage 2–3) | 1.0 ± 0.0 (stage 1) | 3.0 ± 0.78 (stage 3) | < 0.001 |
MPH (cm) | 159.6 ± 3.99 | 158.2 ± 3.17 | 160.8 ± 4.23 | 0.066 |
Basal LH (mIU/mL) | 0.65 ± 0.56 | 0.02 ± 0.35 | 1.32 ± 1.43 | < 0.001 |
Basal FSH (mIU/mL) | 3.71 ± 1.52 | 1.72 ± 0.62 | 4.92 ± 2.54 | < 0.001 |
Basal E2 (pg/mL) | below than 8 | below than 8 | 17.3 ± 3.66 | |
LH peak (mIU/mL) | 14.3 ± 9.4 | |||
FSH peak (mIU/mL) | 20.4 ± 8.8 |